CRMD
HEALTHCARECorMedix Inc
$8.05+0.32 (+4.14%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CRMD Today?
No stock-specific AI insight has been generated for CRMD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.12$17.43
$8.05
Fundamentals
Market Cap$631M
P/E Ratio3.9
EPS$2.04
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.5%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding78.4M
CRMD News
20 articles- The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·May 8, 2026
- CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026Yahoo Finance·May 5, 2026
- CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation PatientsYahoo Finance·Apr 27, 2026
- CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement ShiftMarketbeat·Apr 15, 2026
- Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of DirectorsYahoo Finance·Apr 13, 2026
- How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst TargetsYahoo Finance·Apr 8, 2026
- CorMedix to Participate in Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?Yahoo Finance·Mar 31, 2026
- Do Options Traders Know Something About CorMedix Stock We Don't?Yahoo Finance·Mar 26, 2026
- How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets ResetYahoo Finance·Mar 24, 2026
- CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at LeerinkMarketbeat·Mar 14, 2026
- CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at ConferenceMarketbeat·Mar 14, 2026
- Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth ExpectationsYahoo Finance·Mar 6, 2026
- CorMedix Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- CorMedix Buyback And REZZAYO Data Shape Valuation And Risk ProfileYahoo Finance·Mar 6, 2026
- CorMedix Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Cormedix Inc (CRMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo Finance·Mar 5, 2026
- CorMedix (CRMD) Lags Q4 Earnings EstimatesYahoo Finance·Mar 5, 2026
- CorMedix: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
All 20 articles loaded
Price Data
Open$7.85
Previous Close$7.73
Day High$8.11
Day Low$7.81
52 Week High$17.43
52 Week Low$6.12
52-Week Range
$6.12$17.43
$8.05
Fundamentals
Market Cap$631M
P/E Ratio3.9
EPS$2.04
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.5%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding78.4M
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—